Introduction {#s1}
============

Periodontitis is a site-specific disease that causes periodontal attachment and bone loss ([@b1]). In the general population, periodontitis is a common cause of tooth loss ([@b2]).One of the important goals of periodontal treatment is to reduce the pocket depth ([@b3]). Non-surgical treatment is indicated in cases with moderate periodontitis. On the other hand, standard treatment protocol should be supported with periodontal surgery in the presence of deep pockets and intrabony defects ([@b4]).According to Melcher's hypothesis ([@b5]), the selected cell population in the periodontium can regenerate periodontal tissues provided that the cells could occupy the periodontal wound. Guided tissue regeneration (GTR) is a regenerative technique in which a physical barrier was positioned between the flap and the root surface to prevent the migration of the connective tissue and epithelium. This provides an opportunity for the pluripotent ligament cells to multiply on the root surface ([@b6]).

Tricalcium phosphate (TCP) is an alloplastic bone substitute which has been extensively researched since the 1970's. This resorption rate of this material has been reported to be similar to that of the new bone apposition ([@b7]). Its potential to stimulate the bone formation is higher than hydroxyapatite, but lower than that of the Bioglass ([@b6],[@b8]). SynOss®(Dentacare, Pune, India) is a commercially available pure phase Beta TCP. It meets the purity requirements for bioceramics of the American standards (ASTM F 1088-87). It is biocompatible, carries no risk of disease transmission and shows no immunogenic reactions ([@b9]). SynOss® has unique forms of the granules mimicking the bone macroscopic structure ([@b9]). It fully degrades within 6-12 months which is close to the native bone apposition rate, depending on the patient's individual regeneration potential ([@b10]). Various types of absorbable and non-absorbable materials have been tested as membranes for GTR ([@b11],[@b12]). Perio-Col® GTR is a bio-absorbable Type I collagen membrane manufactured from the air-bladder of edible fresh water fish. Perio-Col® is a non-toxic, non-allergenic and non-immunogenic biocompatible material ([@b13]). Especially when combined with platelet rich plasma, Perio-Col® GTR membrane has shown promising results in the treatment of intra-bony defects ([@b14]).

Mitogenesis, chemotaxis and cell differentiation during the repair and/or regeneration process are regulated by growth factors ([@b15]). Improved osseous defect fill has been reported in patients treated with platelet derived growth factors (PDGF/IGF-I) during its first human clinical trial ([@b16]). PDGF, insulin-like growth factor (IGF) and transforming growth factor- β (TGF-β) enhance wound healing and provoke regeneration([@b17]).PRP's potential in new bone formation was first reported in 1998([@b18]). The aim of the present study is therefore to examine the effect of autologous platelet concentrate on periodontal regeneration when used in combination with an alloplastic bone graft and GTR membrane. The null hypothesis of this research is that no difference can be observed between study and control groups.

Subjects and methods {#s2}
====================

Study participants {#s2a}
------------------

The study was approved by the ethics review and research board (Approval no. 16/2013, MGV 30134/43246). The study design was a randomized clinical case-controlled trial that follows the guidelines cited by CONSORT. Written, informed consents were obtained from all patients. Thirty defects of 14 systemically healthy patients were included. Male to female ratio was 1:1, their age range was 20 to 55 years and mean age was 34 ± 10.57 years.

Patient selection {#s2b}
-----------------

Having no contraindication for periodontal surgery, good oral hygiene habits, having at least two intra-bony defects, one at each quadrant or contra-lateral sides of the same region, having minimum 6 mm of probing pocket depths (PPD) and having radiographic angular bone defect of at least 4 mm at baseline were the inclusion criterion. Patients with more than 1 mm of mobility, prosthetic restoration and/or endodontic treatment in the affected teeth, those who are allergic to drugs, pregnant and/or lactating, smokers or having any other contraindication for periodontal surgery were excluded.

Study design {#s2c}
------------

Thirty selected sites in 14 patients were randomly allocated into either one of the Site A or Site B groups stratified by the treatment plan, each site in different quadrants. Defects in Site A were filled with β-TCP mixed with autologous platelet concentrate (APC) and then covered with absorbable collagen membrane (Perio-Col®-GTR). Defects in site B received also a β-tricalcium β-TCP but no APC and they were again covered with the same collagen membrane. The healing process was recorded by following the baseline scores and those registered after3, 6, and 9 months after surgery. Full mouth plaque index (PI) ([@b19]), full mouth papillary bleeding index (PBI) ([@b20]), PPD, clinical attachment level (CAL), gingival recession (REC) were determined at each time point. A cast model was obtained from alginate impression and occlusal stents from acrylic resin were fabricated for probe positioning ([@b21]).

Radiographic parameters {#s2d}
-----------------------

After initial therapy, standardized radiovisiographs (RVG) (Kodak DS, Rochester, NY, USA)were taken with the RINN XCP system (DENTSPLY, Tulsa, Oklahoma, USA), at baseline, and after 3, 6, and 9 months following surgery. The following landmarks were identified on the radiographs: Cemento-enamel junction (CEJ), base of the defect (BD), alveolar crest (AC), cemento-enamel junction to root apex (RA) ([Figure 1](#fig1){ref-type="fig"}). Pre- and post-treatment radiographs (RVG) pairs were compared to investigate the presence of crestal bone resorption (ACC), bone defect filling (BF) and the extent of defect resolution which was calculated with the following formula: DR= (BF−ACC).

Surgical procedure {#s2e}
------------------

An hour prior to surgery, venous blood was collected and stored in a 10 ml tube that contains 3.2% sodium citrate as anticoagulant. Tubes were then placed in a manual centrifugation device (e-tek, Remi laboratory, India). The first step was completed in 13 minutes at 1000 rpm and the second one in 10 minutes at 2000 rpm. APC was collected from the bottom layer of the test tube ([Figure 2](#fig2){ref-type="fig"}). 10% calcium chloride was added to activate APC, and then the mixture was left undisturbed for 15-20 minutes to ensure a proper gel formation. The surgical procedure was performed under local anesthesia, β-tricalcium phosphate granules (SynOss®) of 300µ - 600µ particle size, were mixed with 2-3 drops of fresh blood from the same defect and then mixed with the coagulated APC ([Figure 3](#fig3){ref-type="fig"}). Bio-absorbable membrane (Perio-Col®) was used for guided tissue regeneration. The membrane was placed and sutured over the defect with absorbable suture material (Vicryl® 4-0 reverse cutting, Ethicon, Johnson and Johnson, India). β-tricalcium phosphate granules mixed with APC was packed in the defect up to the level of the surrounding bony walls ([Figure 4](#fig4){ref-type="fig"}). Mucoperiosteal flaps were then approximated and sutured at their initial position using 3-0 silk. In the control sites, the same procedure was carried out, but β-tricalcium phosphate granules were mixed with normal sterile saline instead of APC, and the root surface was not coated with APC. Recall appointments were made after 1, 3, 6, and 9 months post-surgery for clinical evaluation. Post-operative patients' evaluation was done clinically and radiographically at 3, 6, and 9 months ([Figure 5](#fig5){ref-type="fig"} and [Figure 6](#fig6){ref-type="fig"}).

Statistical analysis {#s2f}
--------------------

All the clinical and radiographic parameters recorded were transferred to Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA), and subjected to the following statistical analysis: the paired-t test was performed to compare intra-group variation, Intergroup variation between the two groups was compared by using a non-parametric, rank test (Mann-Whitney U test). Confidence level was set to 95% and p\<0.05 was considered significant.

Results {#s3}
=======

Of the 14 patients who have completed the study, seven were male and seven were female. The mean baseline PI score was 0.83±0.05 and 0.38±0.17 at 9 months follow up which indicated a significant mean 54% reduction to 0.45±0.19 (p\<0.001) ([Figure 7](#fig7){ref-type="fig"}). Also, the mean PBI score at baseline (0.83±0.19) dropped down to 0.14±0.14 at 9 months which shows significant 84% reduction (0.69±0.22) (p\<0.001) ([Figure 8](#fig8){ref-type="fig"}). The reduction in PPD between the baseline and at 9 months was statistically significant in both experimental site A and experimental site B (p\<0.05). The CAL between baseline and 9 months was statistically significant in both groups (p\<0.05). At 9 month time point, the difference in the mean CAL gain (1.4 mm) was statistically significant (p\<0.05) ([Table 1](#table1){ref-type="table"}). After 9 months from baseline, the mean REC gain was statistically significant in both groups (p\<0.05). The mean REC between the two groups at 6 months and 9 months was 0.86 mm and 1.06 mm respectively which was statistically significant (p\<0.05) ([Table 1](#table1){ref-type="table"}).

Both groups showed a statistically significant (p\<0.001) gain in bone defect fill compared to the baseline and 1, 3 and 9 months, with the maximum reduction recorded at the end of the 9 month follow-up ([Table 1](#table1){ref-type="table"}). The mean defect fill was statistically significant in both groups when the baseline was compared to 1, 3 and 9 months, with the maximum defect fill recorded at the 9 month interval (p\<0.05 for each). Both groups revealed gradual increase in the defect resolution percentage from baseline to 1, 3 and 9 months. A comparison between the two groups revealed a difference of 1.78±0.37%, 3.57±0.69% and 0.50±0.08% at 3 months, 6 months and 9 months respectively, but this was not statistically significant. Figure 1.Radiographic planning of the treatment (A: cemento-enamel junction to alveolar crest, B: cemento-enamel junction to base of the defect, C: root). Figure 2.Autologous platelet concentrate. Figure 3.SynOss mixed with autologous platelet concentrate and patients' blood. Figure 4.Pre-suturing of the membrane and graft placed in the defect. Figure 5.Control site radiographic evaluation at baseline (a), three months (b), six months (c) and 9 months (d). Figure 6.Test site radiographic evaluation at baseline (a), three months (b), six months (c) and 9 months (d). Figure 7.Changes in the mean plaque (PI) and papillary bleeding index (PBI) score over time. Figure 8.Comparison of the percentage of mean radiographic defect resolution over time. Table 1.Presentation of the mean and standard deviations of the study variables stratified by the time point parameter (PPD: pocket probing depth,CAL clinical attachment level,REC: recession coverage,BD: bone defect fill,ACC: alveolar crest change, RED: radiographic extent of bony defect).Experimental Site AExperimental site BPPDCALRECBDACCREDPPDCALRECBDACCREDBase line8.07±1.539.40±1.801.60±1.1811.59±3.564.12±2.347.47±3.717.73±1.398.60±2.030.87± 1.139.57± 2.513.58±1.445.99±2.073 Months3.93±1.285.53±1.411.60±1.128.06±2.914.39±2.953.68±3.114.33±0.905.53±1.511.20± 1.216.75± 3.063.98±1.862.77±1.986 Months3.27±0.964.47±1.461.20±1.086.76±2.784.56±2.922.20±2.483.40±1.184.73±1.831.33± 1.405.99± 2.994.26±2.281.73±1.969 Months2.87±0.833.93±1.331.07±1.035.37±2.274.09±2.981.28±1.173.13±1.194.53±21.40± 1.405.42± 2.903.94±2.101.48±2

Discussion {#s4}
==========

Histologic evidence gathered from experimental studies indicated that the application of growth factors such as PDGF and IGF might be beneficial in the periodontal regenerative therapy when applied in the short term ([@b21],[@b22]). Less post-operative membrane exposures and higher rate of bone apposition have been reported following the use of PRP, β-TCP and GTR up to 6 months although no difference was found at 12 months ([@b23]). However, the treatment of bone defects with β -TCP, β-TCP + PRP and β-TCP + GTR did not show significant differences among 3 groups ([@b24]).

The present study evaluated the effects of growth factors on GTR, by delivering an increased concentration of growth factors directly to the defect site along with the benefit of the barrier action of the collagen membrane and scaffold effect of the β-TCP bone graft. In this study, the platelet density in the resulting APC preparation was higher (573.27%) than the one obtained by Landesberg (18) (205.7%) and Marx ([@b25]) (338%). This difference could be due to variations in the preparation steps such as force or time. Before being applied to the test defect, 10% calcium chloride solution in 6:1 ratio was used to activate the platelet concentrate. This ratio is the minimal amount of CaCl2 to neutralize the citrate and induces the platelet concentrate clotting. In contrast to Marx et al.([@b18]), no xenogenous material such as bovine thrombin was added in order to prevent possible infection or contamination. To accelerate the coagulation process, some drops of collected venous blood were added to the β-TCP before mixing it with APC, which is consistent with the work of Appel et al.([@b26]).

Post-operative membrane exposure rate in the control sites of the present study was 13.33% and no membrane exposure was found at the test sites. Growth factors included in the APC might have therefore positively affected the soft tissue closure in test sites. Consistently, PDGF released from platelet's' α-granules has been reported to show mitogenic and chemotactic effects on fibroblasts and proliferative effects on endothelial cells ([@b27]).

Both test and control groups showed significant reduction in PPD and higher CAL gain after 3, 6, and 9 months compared to baseline values. The PPD reduction and CAL gain was higher in sites treated with APC at 3, 6 and 9 months than those without APC. However, no significant difference was found between the two, although the test site had significantly gained more CAL at 9 months compared to the control site.

All the sites, except for the two in the control group, showed ≥ 3 mm of CAL gain in both groups at the end of 9 months. Around 53.3% of the control and all of the test sites showed CAL gain of ≥ 4 mm at the end of 9 months. Previous studies in which only the membranes were used, CAL gain of at least 4 mm was found in 51.6%, 38.7%, and 69% of cases ([@b28],[@b29]). The lower CAL gain found in the present one could be due its longer duration.

The defect fill variable showed an acceptable outcome. In the test site, the mean defect fill was 30%, 42% and 54% at 3 months, 6 months and 9 months respectively, which was highly significant when compared to baseline values. These findings were consistent with others ([@b30]). A similar pattern was observed in the control sites with a mean defect fill of 29%, 37% and 43% at 3 months, 6 months and 9 months respectively. This was also significant when compared to the baseline which is line with previous research ([@b31]). The difference between the means of two groups, however, was not significant.

Following periodontal surgery, remodeling of the alveolar bone leads to crestal resorption. In the present study, the APC sites showed supracrestal bone formation as compared to the site where APC was not used. However, the results were not statistically significant. In this variable, our findings were not consistent with previous studies where there was no supracrestal bone formation ([@b32]). The results obtained in this study with regards to the gain in alveolar crest height at the end of 9 months could be due to the stickiness of the APC gel as well as the small (300-600μ) particle size of ß-TCP granules. However, the surgical technique used in this study (i.e. pre-suturing of membrane before placement of ß-TCP), could be another reason by preventing the dislodgment of the bone graft due to fresh bleeding because of suturing.

CAL gain found in the present study acted together with significant bone gain in the defects in both groups. The imaging study showed substantial changes in the hard tissue changes compared to those reported in previous research ([@b33],[@b34]). However, this finding should be considered cautiously because of the radiopacity of the bone graft granules. Increased bone turnover rate at 6 weeks after the application of rh-PDGF has been shown previously ([@b35]). In addition, positive effects of growth factor combinations, such as IGF-I and PDGF-BB or TGF-β1 and FGF, on the bone cells' proliferation and activity have been reported in vitro ([@b36]).

Conclusion {#s5}
==========

At 9 months, the PPD reduced and CAL gain increased in both groups. However, the test sites' CAL gain was higher. REC was also more pronounced in the test groups. Both groups showed considerable defect fill rates but no significant difference was observed between them. In addition, although not significant, APC sites showed supracrestal bone formation compared to those without APC. The pre-suturing of the membrane and the use of APC improved the handling properties of β-TCP. APC could have been prepared without the use of bovine thrombin, although it would have taken slightly longer to form a sticky gel and release growth factors.
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